Additional file 2 of Systematic in vivo candidate evaluation uncovers therapeutic targets for LMNA dilated cardiomyopathy and risk of Lamin A toxicity
Creators: name: Tan, Chia Yee
name: Chan, Pui Shi
name: Tan, Hansen
name: Tan, Sung Wei
name: Lee, Chang Jie Mick
name: Wang, Jiong-Wei
name: Ye, Shu
name: Werner, Hendrikje
name: Loh, Ying Jie
name: Lee, Yin Loon
name: Ackers-Johnson, Matthew
name: Foo, Roger S. Y.
name: Jiang, Jianming
Publisher: name: figshare
Year: 2024
Subjects: subject: Biochemistry
subject: Medicine
subject: Cell Biology
subject: Genetics
subject: FOS: Biological sciences
subject: Molecular Biology
subject: Pharmacology
subject: Chemical Sciences not elsewhere classified
subject: Biological Sciences not elsewhere classified
subject: Developmental Biology

description: Additional file 2: Table S1. Effect of potential candidates in wildtype mice. Echocardiography of potential candidates Lamin A at a dose of 1E+13 vg/kg assessed at 5.5 weeks. P value represents comparisons to EGFP control, two-tailed, unpaired T-test with Welch correction and Mann-Whitney test. Table S2. Effect of Lamin A on wildtype mice. Effect of Lamin A at a dose of 2E+13 vg/kg assessed by echocardiography at 5.5 weeks. P value represents comparisons to EGFP control, two-tailed, unpaired T-test with Welch correction. Table S3. Effect of cardiac specific upregulation of mature Lamin A. Effect of mature Lamin A at a dose of 2E+13 vg/kg assessed by echocardiography at 5.5 weeks. P value represents comparisons to EGFP control, two-tailed, unpaired T-test with Welch correction. Table S4. Effect of potential candidates on Lmna DCM in mice. Echocardiography of Lmna DCM mice supplemented with control or potential candidates Sun1 shRNA, Bmp7-Ctgf shRNA, Lamin C, aYAP1, Lamin A, Smad3 shRNA, Yy1, Ctgf shRNA, Bmp7, Fgf16, Smad2 shRNA, Mapk14 shRNA, Yap1 shRNA, Tgfb1 shRNA, Raptor shRNA or Serca2a at a dose of 1E+13 vg/kg assessed at 5.5 weeks. P value represents comparisons to Lmna DCM, Brown-Forsythe and Welch ANOVA test with Dunnett’s T3 correction and Kruskal- Wallis test. LVDD, left ventricular diastolic dimension; LVWT, LV wall thickness; EF, ejection fraction; FS, fractional shortening. *One mouse died before echocardiography. Table S5. Effect of potential candidates in wildtype mice. Echocardiography of potential candidates Lamin C, Sun1, Bmp7-Ctgf shRNA, aYAP1, Smad3 shRNA, Yy1, Ctgf shRNA, Bmp7, Fgf16, Smad2 shRNA, Mapk14 shRNA, Yap1 shRNA, Tgfb1 shRNA, Raptor shRNA or Serca2a or control at a dose of 1E+13 vg/kg assessed at 5.5 weeks. P value represents comparisons to control, Brown-Forsythe and Welch ANOVA test with Dunnett’s T3 correction. Table S6. Effect of selected candidates at higher dose on Lmna DCM mice. Echocardiography of Lmna DCM mice supplemented with control or candidates Smad2 shRNA, Yap1 shRNA, Tgfb1 shRNA, Mapk14 shRNA, Smad3 shRNA, Sun1 shRNA, Yy1, a YAP1 or control at a dose of 2E+13 vg/kg assessed at 5.5 weeks. P value represents comparisons to control, Brown-Forsythe and Welch ANOVA test with Dunnett’s T3 correction. *One mouse died before echocardiography. Table S7. Effect of KASH Domain on Lmna DCM Effect of KASH domain at a dose of 1.0E+13 vg/kg on Lmna DCM mice at 5.5 weeks. P value represented comparisons Lmna DCM + Ctrl, Brown-Forsythe and Welch ANOVA test with Dunnett’s T3 correction. LVDD, left ventricular diastolic dimension; LVWT, LV wall thickness; EF, ejection fraction; FS, fraction shortening. Table S8. Effect of DNSUN1 on inducible Lmna DCM mice Echocardiography of control and inducible Lmna DCM mice performed 2.5 weeks after Lmna deletion. P value represents comparisons to control, two-tailed, unpaired T-test with Welch correction and Mann-Whitney test. LVDD, left ventricular diastolic dimension; LVWT, LV wall thickness; EF, ejection fraction; FS, fractional shortening. Echocardiography performed on a Prospect T1 ultrasound.